Abstract: This invention relates to the treatment of edematous conditions in an animal by administering a neurotensin antagonist having diuretic activity.

Abstract: A compound of formula (VIII): ##STR1## in which Alk is a (C.sub.1 -C.sub.4)alkyl group, R.cndot. is hydrogen or a protecting group cleavable by hydrolysis and R is hydrogen, a protecting group cleavable by reduction or a heterocycle of structure (IX): ##STR2## in which Hal is a halogen atom and X, Y and Z are each --CH.dbd. or one of them is a nitrogen atom and the others are --CH.dbd., and its salts, R.cndot. being other than hydrogen if R is hydrogen or a group of structure (IX).

Abstract: A method is disclosed for the treatment of neuronal degenerative processes. The method comprises administering 1-[4-(3-trifluoromethylphenyl)-1, 2, 3, 6-tetrahydropyrid-1-yl]-2-)6, 7-dimethoxynaphth-2-yl)ethane or a pharmaceutically acceptable salt thereof to a mammal suffering from a neuronal degenerative process.

Abstract: The present invention concerns the use of 4-amino-1-(2-pyridyl)piperidines of general formula (I') ##STR1## wherein R' represents hydrogen, a halogen atom, a methyl, methylthio, trifluoromethyl, trifluoromethylthio, (C.sub.1 -C.sub.3)alkoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, or phenoxy group optionally substituted with a halogen atom, a trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.3)alkylthio, or cyano group, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of those conditions deriving from disorders of the serotoninergic systems wherein a serotoninergic action selectively mediated by the 5-HT.sub.3 receptors is required, e.g. affective disorders, anxiety, psychotic troubles, constipation.

Abstract: New N-substituted 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines useful in the treatment of intestinal motility disorders, of the following general formula ##STR1## wherein A represents a group -E-G or -L-M, where-E- is a straight or branched alkylene radical of from 2 to 4 carbon atoms,-G represents a radical selected from the group consisting of naphthyl mono-substituted with hydroxy or (C.sub.1 -C.sub.4)alkoxy; naphthyl di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl; or napthyl substituted with methylenedioxy,-L- is a -Q-CH(OH)-- group wherein -Q- is a straight or branched alkylene radical of from 1 to 3 carbon atoms, and-M represents a radical selected from the group consisting of naphthyl; naphthyl mono- or di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl or naphthyl substituted with methylenedioxy; pyridyl; or (C.sub.1 -C.sub.4)alkyl-pyridyl,and their salts with mineral or organic acids.

Abstract: New N-substituted 4-(3-trifluoromethylpheny1)-1,2,3,6-tetrahydropyridines useful in the treatment of intestinal motility disorders, of the following general formula ##STR1## wherein A represents a group --E--G or --L--M, where--E-- is a straight or branched alkylene radical of from 2 to 4 carbon atoms,--G represents a radical selected from the group consisting of naphthyl mono-substituted with hydroxy or (C.sub.1 -C.sub.4)alkoxy; naphthyl di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl; or naphthyl substituted with methylenedioxy,--L-- is a --Q--CH(OH)-- group wherein --Q-- is a straight or branched alkylene radical of from 1 to 3 carbon atoms, and--M represents a radical selected from the group consisting of naphthyl; naphthyl mono- or di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl or naphthyl substituted with methylenedioxy; pyridyl; or (C.sub.1 -C.sub.4)alkyl-pyridyl,and their salts with mineral or organic acids.

Abstract: The present invention relates to novel heteroarylpiperidines of formula (I): ##STR1## in which Hal is a halogen atom, Alk is a C.sub.1-4 alkyl group and one of X, Y and Z is a nitrogen atom while the others are .dbd.CH--, and their salts. These compounds are useful as 5-HT.sub.3 agonists.

Abstract: New N-substituted 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines useful in the treatment of intestinal motility disorders, of the following general formula ##STR1## wherein A represents a group --E--G or --L--M, where--E-- is a straight or branched alkylene radical of from 2 to 4 carbon atoms,--G represents a radical selected from the group consisting of naphthyl mono-substituted with hydroxy or (C.sub.1 -C.sub.4)alkoxy; naphthyl di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl; or naphthyl substituted with methylenedioxy,--L-- is a --Q--CH(OH)-- group wherein --Q-- is a straight or branched alkylene radical of from 1 to 3 carbon atoms, and--M represents a radical selected from the group consisting of naphthyl; naphthyl mono- or di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl or naphthyl substituted with methylenedioxy; pyridyl; or (C.sub.1 -C.sub.4)alkyl-pyridyl,and their salts with mineral or organic acids.

Abstract: The present invention relates to novel heteroarylpiperidines of formula (I): ##STR1## in which Hal is a halogen atom, Alk is a C.sub.1 -C.sub.4 alkyl group and X, Y and Z are each --CH.dbd. and their salts, to a process for their preparation and to their use as drugs active as 5-HT.sub.3 agonists.

Abstract: The present invention relates to the novel compound {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino]-5,6,7,8-tetrahydrona phthalen-2-yloxy}acetic acid of formula (I): ##STR1## and its pharmaceutically acceptable salts, which act as .beta..sub.3 -adrenergic agonists, and to the pharmaceutical compositions and laboratory reagents in which it is present.

Abstract: New N-substituted 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines useful in the treatment of intestinal motility disorders, of the following general formula ##STR1## wherein A represents a group --E--G or --L--M, where--E-- is a straight or branched alkylene radical of from 2 to 4 carbon atoms,--G represents a radical selected from the group consisting of naphthyl mono-substituted with hydroxy or (C.sub.1 -C.sub.4)alkoxy; naphthyl di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl; or naphthyl substituted with methylenedioxy,--L-- is a --Q--CH(OH)-- group wherein --Q-- is a straight or branched alkylene radical of from 1 to 3 carbon atoms, and--M represents a radical selected from the group consisting of naphthyl; naphthyl mono- or di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl or naphthyl substituted with methylenedioxy; pyridyl; or (C.sub.1 -C.sub.4)alkyl-pyridyl,and their salts with mineral or organic acids.

Abstract: New N-substituted 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines useful in the treatment of intestinal motility disorders, of the following general formula ##STR1## wherein A represents a group --E--G or --L--M, where --E-- is a straight or branched alkylene radical of from 2 to 4 carbon atoms,--G represents a radical selected from the group consisting of naphthyl mono-substituted with hydroxy or (C.sub.1 -C.sub.4)alkoxy; naphthyl di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl; or naphthyl substituted with methylenedioxy,--L-- is a --Q--CH(OH)-- group wherein --Q-- is a straight or branched alkylene radical of from 1 to 3 carbon atoms, and--M represents a radical selected from the group consisting of naphthyl; naphthyl mono- or di-substituted with hydroxy, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)alkyl or naphthyl substituted with methylenedioxy; pyridyl; or (C.sub.1 -C.sub.4)alkyl-pyridyl,and their salts with mineral or organic acids.

Abstract: The invention concerns a method of treatment and prophylaxis of depression and stress by means of a phenylethanolaminotetralin of formula (I) ##STR1## wherein A is a (C.sub.1 -C.sub.4)alkylene radical and R represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, or a pharmaceutically acceptable salts thereof.

Abstract: A method of prophylaxis and/or treatment of intestinal motility disorders, in particular of constipation, in mammals which comprises administering to a mammal in need of such a treatment a prophylactically and/or therapeutically effective amount of a compound of formula (I) ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene radical, andR represents a cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, p-tolyl, pyridyl, pyridyl 1-oxide, or naphthyl group, or of a pharmaceutically acceptable salt thereof.

Abstract: A method of prophylaxis and/or treatment of intestinal motility disorders, in particular of constipation, in mammals which comprises administering to a mammal in need of such a treatment a prophylactically and/or therapeutically effective amount of a compound of formula (I) ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene radical, andR represents a cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, p-tolyl, pyridyl, pyridyl 1-oxide, or naphthyl group, or of a pharmaceutically acceptable salt thereof.

Abstract: Phenylethanolamine analog active compounds, optionally substituted on the phenyl group with an halogen atom or with an alkyl or trifluoromethyl group and substituted on the amino group with a phenylalkyl or phenoxy alkyl group optionally substituted on the benzene ring, are used for the treatment and/or prophylaxis of gastrointestinal diseases associated with a smooth muscle contraction.

Abstract: A novel phenylethanolaminotetraline having lipolytic activity of formula ##STR1## wherin X represents hydrogen, halogen, a trifluoromethyl or a lower alkyl group and R represents hydrogen, a lower alkyl group not substituted or substituted by a cycloalkyl group containing 3 to 7 carbon atoms, a hydroxy group, a lower alkoxy, carboxy or lower carbalkoxy group; a cycloalkyl group containing 3 to 7 carbon atoms; or a lower alcanoyl group; or a pharmaceutically acceptable salt thereof; a process for its preparation; and pharmaceutical compositions containing it as active ingredient, useful for the treatment of obesity.